Tag: Pharmaceutical industry
Eli Lilly’s Zepbound Weight Loss Drug No Longer in Shortage – FDA Update
In the bustling city of New York, Eli Lilly's Zepbound weight loss drug was making headlines, but now the story has taken a surprising turn. The Food and Drug Administration (FDA) recently announced a...
FDA Approves Eli Lilly’s Zepbound Weight Loss Drug for Sleep Apnea in the U.S.
FDA Approves Eli Lilly's Zepbound Weight Loss Drug for Sleep Apnea in the U.S.The Food and Drug Administration recently gave the green light to Eli Lilly's Zepbound injection pen as a groundbreaking...
Merck to Develop Weight Loss Pill from Chinese Drugmaker in $2B Licensing Deal
Merck Secures $2B Licensing Deal for Weight Loss Pill
Merck, the pharmaceutical giant based in Rahway, New Jersey, has announced a groundbreaking $2 billion licensing deal with Chinese drugmaker Hansoh Pharma. This deal grants Merck...
Comparison: Eli Lilly vs. Novo Nordisk in Weight-Loss Market
Eli Lilly, a company based in the United States, may have been a bit late to the game, but they are certainly making up for lost time in the battle of the bulge against...
Threat to Big Pharma’s Profits in America
Pharma bosses, oh boy, let me tell you about them. For America’s politicians, they're like the easiest target to go after. According to Gallup, only a fifth of the country really likes them. That's...
Affordable Wegovy Available Directly from Novo Nordisk – Limited Time Offer
Novo Nordisk's Wegovy weight loss drug, known for its soaring popularity, is now more accessible than ever with a groundbreaking offer directly from the pharmaceutical giant. In an effort to make this blockbuster injection...
Eli Lilly’s $27 Billion U.S. Manufacturing Investment Plan
Eli Lilly's Multi-Billion Dollar Manufacturing Investment PlanEli Lilly, a pharmaceutical giant based in Indianapolis, Indiana, has recently made headlines with its bold announcement to invest a whopping $27 billion in building four new manufacturing...
Future of Weight Loss Drugs: Insights from Eli Lilly’s Top Scientist
Dan Skovronsky, the chief scientific officer at Eli Lilly, is at the forefront of developing groundbreaking obesity drugs. With the success of Zepbound, a weekly shot from the pharmaceutical giant, Skovronsky is now focused...
Bluebird Bio Sells Itself to Private Equity Amid Challenges
Bluebird Bio: A Story of Innovation, Struggles, and a New BeginningAfter years of pioneering gene therapies and promising groundbreaking treatments, Bluebird Bio has announced its sale to private equity firms Carlyle and SK Capital...
Biogen exceeds estimates with Leqembi, but profit outlook disappoints
Biogen's Leqembi Soars, but Profit Forecast Falls ShortBiogen, a renowned biotech company, recently released its fourth-quarter financial results, exceeding revenue and profit expectations thanks to cost-saving efforts and successful new products, notably their groundbreaking...
Investors and Big Pharma Seek New Medicines in China
Investors and Big Pharma Seek New Medicines in ChinaA groundbreaking shift is taking place in the biopharmaceutical industry, as investors and major pharmaceutical companies are increasingly turning to China in search of innovative medicines....
CVS CEO Defends Pharmacy Middlemen Against Drugmakers’ Monopolistic Practices
David Joyner, the CEO of CVS Health, stood before the Senate Health, Education, Labor and Pensions Committee in Washington, D.C., on May 10, 2023, to defend pharmacy middlemen like his company's Caremark unit. These...
